Get Updates

Research & Clinical Trials

FORCE has a strong commitment to promoting research to benefit our community. We advocate for more research funding, educate people about available studies, and report findings back to our community.

| More

Featured Research

For a listing of other research studies recruiting patients please visit our Active Studies page.

POLO - Pancreatic Cancer Study
POLO - Pancreatic Cancer Study

POLO is a research study asking the question does maintenance therapy with olaparib (a PARP inhibitor) benefit patients with pancreas cancer associated with mutation of the BRCA gene.

Brocade3
Brocade3

Brocade3 is a research study evaluating the safety and effectiveness of an investigational medication in addition to treatment with chemotherapy for patients with metastatic or locally advanced BRCA associated, HER2-negative breast cancer. For more information, ask your doctor about the Brocade3 Study or visit www.Brocade3Study.com to see if you may qualify!

BRAVO
BRAVO

A study investigating the PARP inhibitor niraparib for women with previously treated HER2 negative, BRCA positive breast cancer.

INFORM Study
INFORM Study

A study for newly-diagnosed breast cancer patients who carry a BRCA1 or BRCA2 mutation.

QUADRA
QUADRA

A study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least 3 previous chemotherapy regimens (which may have included a PARP inhibitor).

ARIEL2
ARIEL2

ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer.

Healthy 1000
Healthy 1000

Healthy 1000 is a study to look at the utility of circulating tumor DNA in asymptomatic subjects for the detection of cancer.

ABOUT Patient Powered Research Network
ABOUT Patient Powered Research Network

The ABOUT Network is the first-ever patient-powered research registry created and governed by and for people affected by HBOC.

ARIEL 3
ARIEL 3

ARIEL3 is a Phase 3 study comparing the effects of the PARP inhibitor, rucaparib, versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

FORCE Research Surveys
FORCE Research Surveys

FORCE conducts surveys to better understand and address the needs of our community. By participating, you can help advance hereditary breast and ovarian cancer research.

Salpingectomy Research Registry
Salpingectomy Research Registry

Study for women who have had their fallopian tubes surgically removed and kept one or both of your ovaries to reduce their ovarian cancer risk.

Basser Research Center for BRCA
Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.

POLO - Pancreatic Cancer Study POLO - Pancreatic Cancer Study

POLO is a research study asking the question does maintenance therapy with olaparib (a PARP inhibitor) benefit  patients with  pancreas cancer associated with mutation of the BRCA gene whose tumor has not grown on an  initial platinum containing drug regimen but who would otherwise be now getting  a break or pause  in their chemotherapy.

More Information

Brocade3 Brocade3

Brocade3 is a research study evaluating the safety and effectiveness of an investigational medication in addition to treatment with chemotherapy for patients with metastatic or locally advanced BRCA associated, HER2-negative breast cancer. For more information, ask your doctor about the Brocade3 Study or visit www.Brocade3Study.com to see if you may qualify!

More Information

BRAVO BRAVO

BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive (hereditary) breast cancer that has progressed after previous treatment. The study will look at how well niraparib (a PARP inhibitor) works compared with standard chemotherapy. Patients will be randomized 2 to 1 so that two patients will take niraparib and one will take their doctor’s choice of chemotherapy. Collaborators for this international trial include the Breast International Group (BIG) and the European Organisation for Research and Treatment of Cancer (EORTC).

Visit clinicaltrials.gov at: http://clinicaltrials.gov/ct2/show/NCT01905592 or http://www.tesarobio.com


 

More Information

INFORM Study INFORM Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited abnormality (mutation) in one of the breast cancer genes, BRCA1 or BRCA2. 

More Information

QUADRA QUADRA

QUADRA is a study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least 3 previous chemotherapy regimens (which may have included a PARP inhibitor). The study will evaluate the antitumor activity of niraparib (an oral PARP inhibitor).  Women with and without germline BRCA mutations can participate, and testing will be done as part of the study.   All participants will receive niraparib.  

For more information visit:

www.tesarobio.com or Clinicaltrials.gov

More Information

ARIEL2 ARIEL2

ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer.  ARIEL2 is now enrolling its expansion phase to include patients who have failed three lines of prior chemotherapy and are platinum sensitive or platinum resistant.  All patients enrolled in the study will receive the PARP inhibitor rucaparib.

More Information

Healthy 1000 Healthy 1000

Pathway Genomics has developed an experimental assay that will detect circulating tumor DNA examining well-studied mutations in genes associated with the development and progression of cancer. The study investigates the utility of ctDNA in asymptomatic subjects for the detection of cancer. To participate, you must not have received a personal diagnosis in the past, and be over the age of 50, or if between 18-50 years old, be at a known increased risk for breast, ovarian, colon, lung, pancreatic, or thyroid cancers, or melanoma. Visit www.pathway.com/healthy1000/ or https://clinicaltrials.gov/ct2/show/record/NCT02612350

More Information

ABOUT Patient Powered Research Network ABOUT Patient Powered Research Network

ABOUT is the first ever research registry created and governed byand for people affected by HBOC. The ABOUT Network is a "patient-powered" research registry and one of only 29 networks chosen for participation in the National Patient Centered Outcomes Research Network (known as PCORnet). Our goal is to enroll as many Americans with HBOC as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

More Information

ARIEL 3 ARIEL 3

ARIEL3 is a Phase 3 study comparing the effects of the PARP inhibitor, rucaparib, versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer. Two thirds of the participants enrolled in this study will receive rucaparib. The other third of participants will receive placebo.  If you qualify for the ARIEL3 trial, you will receive the following as part of the study: study-related physical exams, lab tests results including BRCA and the biomarker test results, the study medication (rucaparib) or placebo.
 

More Information

FORCE Research Surveys FORCE Research Surveys

FORCE conducts surveys and partners with researchers who conduct surveys to better understand and address the needs of our community. By participating in surveys for which you are eligible, you help promote and advance hereditary breast and ovarian cancer research.

More Information

Salpingectomy Research Registry Salpingectomy Research Registry

Have you had your fallopian tubes surgically removed and kept one or both of your ovaries? Did you have this surgery to reduce your ovarian cancer risk? Researchers at the University of Washington in collaboration with Facing Our Risk of Cancer Empowered (FORCE) are studying the long-term outcomes of prophylactic salpingectomy (removal of the fallopian tubes). To learn more about this research study, call 206-685-7927 or email kagnew@uw.edu. They cannot ensure the confidentiality of any information sent by e-mail.

More Information

Basser Research Center for BRCA Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center. 

More Information

Learn about the latest breakthroughs in research and our ABOUT Network.

Featured Research

With input from our Scientific Advisory Board, FORCE critically evaluates new research articles on topics of interest to our community and makes the science understandable and accessible to our community.

Join the ABOUT Network

The goal of the ABOUT network is to enroll as many Americans with HBOC risk as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

FORCE:Facing Our Risk of Cancer Empowered